Notices. Notice

5,162 words·~23 min read·/register/2006/04/27/06-3994·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 6715-01-M FEDERAL MARITIME COMMISSION Notice of Request for Additional Information The Commission gives notice that it has requested that the parties to the below listed agreement provide additional information pursuant to section 6(d) of the Shipping Act of 1984, 46 U.S.C. app. 1701 *et seq.* This action prevented the agreement from becoming effective as originally scheduled. Interested parties will have fifteen days from date of publication to file comments on the agreement. *Agreement No.:* 011950. *Title:* HSDG/FOML Agreement. *Parties:* Hamburg-Sud and FESCO Ocean Management, Limited.

By order of the Federal Maritime Commission. Dated: April 24, 2006. Bryant L. VanBrakle, Secretary. [FR Doc. E6-6350 Filed 4-26-06; 8:45 am] BILLING CODE 6730-01-P GENERAL SERVICES ADMINISTRATION Office of Small Business Utilization; Small Business Advisory Committee Notification of a Public Meeting of the Small Business Advisory Committee AGENCY: Office of Small Business Utilization, GSA. ACTION: Notice. SUMMARY: The General Services Administration

(GSA)is announcing a public meeting of the GSA Small Business Advisory Committee (the Committee). DATES: The meeting will take place May 15, 2006. The meeting will begin 9:00 a.m. and conclude no later than 5:00 p.m. that day. The Committee will accept oral public comments at this meeting and has reserved a total of thirty minutes for this purpose. Members of the public wishing to reserve speaking time must contact Aaron Collmann in writing at: *sbac@gsa.gov* or by fax at

(202)501-2590, no later than one week prior to the meeting. ADDRESSES: GSA Expo 2006, Henry B. Gonzalez Convention Center Room 007A, 200 E. Market St., San Antonio, TX 78205. FOR FURTHER INFORMATION CONTACT: Aaron Collmann, Room 6029, GSA Building, 1800 F Street, NW., Washington, DC 20405

(202)501-1021 or email at *sbac@gsa.gov* . SUPPLEMENTARY INFORMATION: This notice is published in accordance with the provisions of the Federal Advisory Committee Act

(FACA)(Pub. L. 92-463). The purpose of this meeting is to develop the topics generated during the previous meeting February 21-22, 2006; to receive briefings from small business topical experts, and to hear from interested members of the public on proposals to improve GSA’s small business contracting performance. Topics to be discussed from the previous meeting may include, but are not limited to, Size Certification, Contract Bundling, and the GSA Schedules Program. Information from previous meetings can be found online at *http://www.gsa.gov/sbac* . Dated: April 21, 2006 Felipe Mendoza, Associate Administrator, Office of Small Business Utilization, General Services Administration. [FR Doc. E6-6360 Filed 4-26-06; 8:45 am] BILLING CODE 6820-34-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Solicitation of Nominations for Membership on the Secretary's Advisory Committee on Human Research Protections AGENCY: Office of Public Health and Science, Office of the Secretary, HHS. ACTION: Notice. Authority: 42 U.S.C. 217a, section 222 of the Public Health Service Act, as amended. The Committee is governed by the provisions of Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees. SUMMARY: The Office for Human Research Protections (OHRP), a program office in the Office of Public Health and Science, Department of Health and Human Services (HHS), is seeking nominations of qualified candidates to be considered for appointment as members of the Secretary's Advisory Committee on Human Research Protections (SACHRP). SACHRP provides advice and recommendations to the Secretary, HHS, and the Assistant Secretary for Health on matters pertaining to the continuance and improvement of functions within the authority of HHS directed toward protections for human subjects in research. SACHRP was established by the Secretary, HHS, on October 1, 2002. OHRP is seeking nominations of qualified candidates to fill four positions on the Committee membership that will become vacant on January 3, 2007. DATES: Nominations for membership on the Committee must be received no later than May 30, 2006. ADDRESSES: Nominations should be mailed or delivered to: Dr. Bernard Schwetz, Director, Office for Human Research Protections, Department of Health and Human Services, 1101 Wootton Parkway, Suite 200; Rockville, MD 20852. Nominations will not be accepted by e-mail or by facsimile. FOR FURTHER INFORMATION CONTACT: Ms. Catherine Slatinshek, Executive Director, SACHRP, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852, telephone: 1-240-453-6900. A copy of the Committee charter and list of the current membership can be obtained by contacting Ms. Slatinshek or by accessing the SACHRP Web site at *http://www.hhs.gov/ohrp/sachrp,* or requesting via e-mail at *sachrp@osophs.dhhs.gov.* SUPPLEMENTARY INFORMATION: The Committee shall advise on matters pertaining to the continuance and improvement of functions within the authority of HHS directed toward protections for human subjects in research. Specifically, the Committee will provide advice relating to the responsible conduct of research involving human subjects with particular emphasis on: Special populations, such as neonates and children, prisoners, and the decisionally impaired; pregnant women, embryos, and fetuses; individuals and populations in international studies; populations in which there are individually identifiable samples, data, or information; and investigator conflicts of interest. In addition, the Committee is responsible for reviewing selected ongoing work and planned activities of the OHRP and other offices/agencies within HHS responsible for human subjects protection. These evaluations may include, but are not limited to, a review of assurance systems, the application of minimal research risk standards, the granting of waivers, education programs sponsored by OHRP, and the ongoing monitoring and oversight of institutional review boards and the institutions that sponsor research. Nominations The Office for Human Research Protections is requesting nominations to fill four positions for voting members of SACHRP. The positions will become vacant on January 3, 2007. Nominations of potential candidates for consideration are being sought from a wide array of fields, including, but not limited to public health and medicine, behavioral and social sciences, health administration, and biomedical ethics. To qualify for consideration of appointment to the Committee, an individual must possess demonstrated experience and expertise in any of the several disciplines and fields pertinent to human subjects protection and/or clinical research. The individuals selected for appointment to the Committee will serve as voting members. The individuals selected for appointment to the Committee can be invited to serve a term of up to four years. Committee members receive a stipend and, when applicable, reimbursement for per diem and any travel expenses incurred, for attending Committee meetings and conducting other business in the interest of the Committee. Nominations should be typewritten. The following information should be included in the package of material submitted for each individual being nominated for consideration:

(1)A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination ( *i.e.* , specific attributes which qualify the nominee for service in this capacity), and a statement that the nominee is willing to serve as a member of the Committee;

(2)the nominator's name, address, and daytime telephone number, and the home and/or work address, telephone number, and e-mail address of the individual being nominated; and

(3)a current copy of the nominee's curriculum vitae. The names of Federal employees should not be nominated for consideration of appointment to this Committee. The Department makes every effort to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee's function. Every effort is made to ensure that a broad representation of geographic areas, females, ethnic and minority groups, and the disabled are given consideration for membership on HHS Federal advisory committees. Appointment to this Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Nominations must state that the nominee is willing to serve as a member of SACHRP and appears to have no conflict of interest that would preclude membership. Potential candidates are required to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest. Dated: April 21, 2006. Bernard A. Schwetz, Director, Office for Human Research Protections, Executive Secretary, Secretary's Advisory Committee on Human Research Protections. [FR Doc. E6-6311 Filed 4-26-06; 8:45 am] BILLING CODE 4150-36-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Injury Prevention and Control Initial Review Group In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention

(CDC)announce the following meeting: *Name:* National Center for Injury Prevention and Control (NCIPC) Initial Review Group

(IRG)*Times and Dates:* 10 a.m.-10:30 p.m., May 23, 2006. 8 a.m.-6:30 p.m., May 24, 2006. 8:30 a.m.-6 p.m., May 25, 2006. *Place:* Doubletree Club Atlanta Airport, 3400 Norman Berry Drive, Atlanta, GA 30344. *Status:* Open: 10 a.m.-11 a.m., May 23, 2006, Closed: 11 a.m.-10:30 p.m., May 23, 2006, Closed: 8 a.m.-6:30 p.m., May 24, 2006, Closed: 8:30 a.m.-6 p.m., May 25, 2006. *Purpose:* This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focuses on prevention and control. *Matters to be Discussed:* Agenda items include an overview of the injury program, discussion of the review process and panelists' responsibilities, and the review of and vote on applications. Beginning at 11 a.m., May 23, through 6 p.m., May 25, the Group will review individual research grant and cooperative agreement applications submitted in response to two Fiscal Year 2006 Requests for Applications related to the following individual research announcements: #06008, Urban Partnership Academic Center of Excellent and #06006, Parenting Programs in the Prevention of Child Maltreatment. This portion of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to section 10(d) of Public Law 92-463. Agenda items are subject to change as priorities dictate. *For Further Information Contact:* Gwendolyn H. Cattledge, Ph.D., M.S.E.H., Executive Secretary, NCIPC IRG, CDC, 4770 Buford Highway, NE., M/S K02, Atlanta, Georgia 30341-3724, telephone

(770)488-1430. The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 20, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6-6349 Filed 4-26-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006F-0059] Danisco USA, Inc.; Filing of Food Additive Petition; Amendment AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is amending the filing notice for a food additive petition filed by Danisco USA, Inc., to indicate that the petition proposes to amend the food additive regulations at 21 CFR 172.841 by incorporating by reference the specifications for polydextrose in the 5th edition of the Food Chemicals Codex (FCC), 2003. ADDRESSES: Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Paul C. DeLeo, Center for Food Safety and Applied Nutrition (HFS-265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-1302. SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of February 15, 2006 (71 FR 7975), FDA announced that a food additive petition (FAP 6A4763) had been filed by Danisco USA, Inc., 440 Saw Mill River Rd., Ardsley, NY 10502-2605. The petition proposed to amend the food additive regulations in § 172.841 Polydextrose (21 CFR 172.841) to provide for the safe use of polydextrose as a bulking agent, formulation aid, humectant, and texturizer in all foods, except meat and poultry. After publication of the filing notice, FDA learned that the petition also proposed to update § 172.841 by incorporating by reference the specifications for polydextrose in the FCC, 5th ed., 2003. Currently, § 172.841 incorporates by reference the specifications of FCC, 4th ed., 1996. The agency compared specifications in the monograph for polydextrose in the 4th and 5th editions of the FCC and found that the 5th edition retains the lead limit of 0.5 milligram(mg)/ kilogram(kg), but no longer lists a specification limit of 5 mg/kg for heavy metals as lead. The 5th edition of the FCC eliminated the heavy metals as lead test from most monographs in favor of including individual specifications for relevant heavy metals. In addition, the 5th edition added a nickel specification of 2 mg/kg for hydrogenated polydextrose, as well as modified the pH specification of a 10 percent solution of untreated polydextrose from “not less than 2.5” (4th edition) to “between 2.5 and 7.0” (5th edition). The name of the specification for 5-Hydroxymethylfurfural has also changed from “5-Hydroxymethylfurfural” (4th edition) to “5-Hydroxymethylfurfural and Related Compounds” (5th edition), although the test and equation used to determine the level have remained the same. The agency has placed copies of the polydextrose monograph in the 4th and 5th editions of the FCC on public display at the Division of Dockets Management (see ADDRESSES ) for public review. Dated: March 30, 2006. Laura M. Tarantino, Director, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition. [FR Doc. E6-6370 Filed 4-26-06; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2005D-0202] Guidance for Industry on Bar Code Label Requirements—Questions and Answers; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing the availability of a guidance for industry entitled “Bar Code Label Requirements—Questions and Answers.” FDA regulations require certain human drug and biological products to have on their labels a linear bar code that identifies the drug's National Drug Code

(NDC)number. We have received several inquiries about how the requirements apply to specific products or circumstances. The purpose of the guidance is to respond to the questions. DATES: Submit written or electronic comments on agency guidances at any time. ADDRESSES: Submit written requests for single copies of this guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or the Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. FOR FURTHER INFORMATION CONTACT: *For products regulated by the Center for Drug Evaluation and Research* : Valerie L. Whipp, Center for Drug Evaluation and Research (HFD-310), Food and Drug Administration, 11919 Rockville Pike, Rockville, MD 20852, 301-827-8963. *For products regulated by the Center for Biologics Evaluation and Research* : Elizabeth Callaghan, Center for Biologics Evaluation and Research (HFM-370), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-8963. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a guidance for industry entitled “Bar Code Label Requirements—Questions and Answers.” In the **Federal Register** of February 26, 2004 (69 FR 9120), FDA issued a final rule that requires certain human drug and biological product labels to have a bar code containing the drug's NDC number. Bar codes will help reduce the number of medication errors in hospitals and other health care settings by allowing health care professionals to use bar code scanning equipment to verify that the right drug (in the right dose and right route of administration) is being given to the right patient at the right time. This guidance is intended to explain certain bar code labeling requirements and their application to human drug and biological products. In the **Federal Register** of June 7, 2005 (70 FR 33182), FDA announced the availability of a draft version of this guidance. FDA received comments in response to the draft guidance. The agency has considered those comments carefully and has revised the answer to Question 7 (which has been renumbered to Question 9) regarding the application of the 2-year implementation date. In response to recent inquiries from a trade association, the agency has also added Questions 3 and 4 regarding the application of the bar code labeling requirements to over-the-counter drug products. In addition, the agency has made minor editorial changes to the guidance. This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the agency's current thinking on certain questions and answers on bar code labeling requirements. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments regarding this document. Submit a single copy of electronic comments or two pape r copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. III. Electronic Access Persons with access to the Internet may obtain the document at *http://www.fda.gov/cder/guidance/index.htm* , *http://www.fda.gov/cber/guidelines.htm* , or *http://www.fda.gov/ohrms/dockets/default.htm* . Dated: April 20, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6-6312 Filed 4-26-06; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006D-0108] Draft “Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs;” Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing the availability of a draft document entitled “Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs,” dated April 2006. The draft guidance document further explains the requirements on informed consent as they relate to plasmapheresis and immunization programs. The draft guidance document is designed to assist blood establishments planning to apply for licensure or those revising their existing informed consent forms in determining whether the documents include all the appropriate information. This draft guidance, when finalized, will supersede the draft guidance document entitled “Draft Reviewer's Guide: Informed Consent for Plasmapheresis/Immunization,” dated October 1995. DATES: Submit written or electronic comments on the draft guidance by July 26, 2006 to ensure their adequate consideration in the preparation of the final guidance. General comments on agency guidance documents are welcome at any time. ADDRESSES: Submit written requests for single copies of the draft guidance to the Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling the CBER Voice Information System at 1-800-835-4709 or 301-827-1800. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit written comments on the draft guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . FOR FURTHER INFORMATION CONTACT: Joseph L. Okrasinski Jr., Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-6210. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft document entitled “Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs,” dated April 2006. The draft guidance further explains the requirements under part 640 (21 CFR part 640) in 21 CFR 640.61 for the informed consent forms for the donors as they relate to plasmapheresis and immunization programs. The information in the draft guidance will assist those establishments applying for licensure as well as those establishments that are revising their existing informed consent forms. The draft guidance discusses information that is recommended for the informed consent forms. This information includes, but is not limited to, the following: Clarity of the language in the informed consent form, length and frequency of the procedures, possible adverse reactions, side affects that may occur, opportunities to ask questions, and discussion concerning Acquired Immunodeficiency Syndrome (AIDS). Also discussed in the draft guidance is the use of a separate informed consent form for a donor who is participating in an immunization program including one which involves an Investigational New Drug (IND), and its recommended informational content, such as the discussion of the general risks and precautions involved, and suggestions for the health and welfare of the participants. This draft guidance when finalized will supersede the draft guidance document entitled, “Draft Reviewer's Guide: Informed Consent for Plasmapheresis/Immunization,” dated October 1995. The draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act This draft guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget

(OMB)under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collection of information under §§ 640.61 and 640.66 was approved under OMB control number 0910-0116. III. Comments The draft guidance is being distributed for comment purposes only and is not intended for implementation at this time. Interested persons may submit written or electronic comments to the Division of Dockets Management (see ADDRESSES ) regarding the draft guidance. Submit written or electronic comments to ensure adequate consideration in preparation of the final guidance. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in the brackets in the heading of this document. A copy of the guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. IV. Electronic Access Persons with access to the Internet may obtain the guidance at either *http://www.fda.gov/cber/guidelines.htm* or *http://www.fda.gov/ohrms/dockets/default.htm* . Dated: April 19, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6-6314 Filed 4-26-06; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration C.W. Bill Young Cell Transplantation Program: National Cord Blood Inventory; Recognition of Cord Blood Bank Accreditation Program(s) AGENCY: Health Resources and Services Administration (HRSA), HHS. ACTION: Notice of opportunity for public comment through conference calls. SUMMARY: Public Law 109-129 requires the Secretary of Health and Human Services to recognize one or more cord blood accreditation entities for the accreditation of cord blood banks participating in the collection and maintenance of umbilical cord blood units for the National Cord Blood Inventory. These cord blood units will be made available for unrelated donor blood stem cell transplants through the C.W. Bill Young Cell Transplantation Program. The HRSA, Healthcare Systems Bureau (HSB), Division of Transplantation

(DoT)is in the process of information-gathering to assist in the determination of which cord blood bank accreditation program(s) to recognize on an interim basis for the initial cycle of funding for the National Cord Blood Inventory. The purpose of this solicitation is to receive public input on the following:

(1)Approaches to accreditation required to ensure quality cord blood bank operations (including collection sites);

(2)Utilization of accreditation programs to ensure product quality and best practices;

(3)Degree to which accreditation standards are evidence based and supported by published literature;

(4)Extent to which accreditation standards allow for variations in cord blood bank practices;

(5)Criteria for the Secretary to consider in recognizing cord blood bank accrediting programs for the National Cord Blood Inventory, C.W. Bill Young Cell Transplantation Program. The HRSA intends for this interim process to be followed by a formal, more comprehensive recognition process that will include input from both the Advisory Council, once it is established, and the interested public as required in the legislation. The purpose of this Notice is to invite interested parties to register for and participate in either of two conference calls, described below, that HRSA is scheduling to obtain comment on factors relevant to determining which accrediting organization(s) to recognize for the initial cycle of funding under the National Cord Blood Inventory. DATES: The conference calls will be held on May 9, 2006, at 2 to 4 p.m. e.s.t. and May 15, 2006, at 2 p.m. to 4 p.m. e.s.t. Participants are asked to register for the conference by contacting Anita Wabeke at

(301)443-4747 or e-mail *awabeke@hrsa.gov.* The registration deadline is May 3, 2006 for both conferences. Registration is not guaranteed; it is on a first come basis. Since the topics listed above will be discussed on both calls, and to facilitate hearing all points of view, HRSA requests that organizations and individuals wishing to participate do so in only one of the calls. Due to the limited number of lines available for the calls, organizations with multiple participants are encouraged to register for one line to allow maximum participation from all interested parties. Parties wishing to submit written comments should ensure that the comments are postmarked or E-mailed no later than May 17, 2006 for consideration. ADDRESSES: Please send all written comments to James F. Burdick, M.D., Director, DoT, HSB, HRSA, Room 12C-06, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857; telephone

(301)443-7577; fax

(301)594-6095; or e-mail: *jburdick@hrsa.gov.* FOR FURTHER INFORMATION CONTACT: James F. Burdick, M.D., Director, DoT, HSB, HRSA, Parklawn Building, Room 12C-06, 5600 Fishers Lane, Rockville, Maryland 20857; telephone

(301)443-7577; fax

(301)594-6095; or e-mail: *jburdick@hrsa.gov.* SUPPLEMENTARY INFORMATION: Background On December 20, 2005, the Stem Cell Therapeutic Act of 2005 was enacted as Public Law 109-129. The Act authorizes the establishment of the National Cord Blood Inventory and the C.W. Bill Young Cell Transplantation Program as the successor to the National Bone Marrow Donor Registry. The National Cord Blood Inventory is to be a high quality, genetically diverse inventory of cord blood units for patients who need a blood stem cell transplant and who lack an available related donor. The cord blood units in the National Cord Blood Inventory will be made available for transplantation through the C.W. Bill Young Cell Transplantation Program. Cord blood banks collecting and maintaining units for the National Cord Blood Inventory must meet the statutory definition of a qualified cord blood bank, which includes a requirement that cord blood banks be accredited by an accreditation entity recognized by the Secretary for this purpose. Program Authority The C.W. Bill Young Cell Transplantation Program is authorized by Public Law 109-129, which amends Part I of the Public Health Service Act. Dated: April 20, 2006. Elizabeth M. Duke, Administrator. [FR Doc. E6-6313 Filed 4-26-06; 8:45 am] BILLING CODE 4165-15-P DEPARTMENT OF HOMELAND SECURITY [Docket No. NCS-2006-0004] Preparedness Directorate; National Security Telecommunications Advisory Committee AGENCY: Preparedness Directorate, DHS. ACTION: Notice of partially closed advisory committee meeting. SUMMARY: The President's National Security Telecommunications Advisory Committee (NSTAC) will meet in a partially closed session. DATES: Wednesday, May 10, 2006, from 9:15 a.m. until 3:30 p.m. ADDRESSES: The meeting will take place at the Ronald Reagan Building and International Trade Center, Washington, DC. If you desire to submit comments, they must be submitted by May 2, 2006. Comments must be identified by NCS-2006-0004 and may be submitted by *one* of the following methods: • Federal eRulemaking Portal: *http://www.regulations.gov.* Follow the instructions for submitting comments. • E-mail: *NSTAC@dhs.gov.* Include docket number in the subject line of the message. • Mail: Office of the Manager, National Communications System (N5), Department of Homeland Security, Washington, DC 20529. *Instructions:* All submissions received must include the words “Department of Homeland Security” and NCS-2006-0004, the docket number for this action. Comments received will be posted without alteration at *http://www.regulations.gov,* including any personal information provided. *Docket:* For access to the docket to read background documents or comments received by the NSTAC, go to *http://www.regulations.gov.* FOR FURTHER INFORMATION CONTACT: Ms. Kiesha Gebreyes, Chief, Industry Operations Branch at

(703)235-5525, e-mail: *kiesha.gebreyes@dhs.gov* or write the Deputy Manager, National Communications System, Department of Homeland Security, IP/NCS/N5. SUPPLEMENTARY INFORMATION: The NSTAC advises the President of the United States on issues and problems related to implementing national security and emergency preparedness (NS/EP) telecommunications policy. Notice of this meeting and the partial closure thereof is given under the Federal Advisory Committee Act (FACA), Pub. L. 92-463, as amended (5 U.S.C. App. 1 *et seq.* ). At the upcoming meeting, between 9:15 a.m. and 10:15 a.m., the committee will discuss ongoing NSTAC task force work of the Emergency Communications & Interoperability Task Force, Telecommunications and Electric Power Interdependency Task Force, Legislative and Regulatory Task Force, and Research and Development Task Force. This portion of the meeting will be open to the public. Following the morning Business Session, the committee will hold an Executive Session between the hours of 10:30 a.m. and 3:30 p.m. to discuss emergency communications & interoperability, international implications of the NGN, and regional coordination, planning, and exercises. The Executive Session will conclude with a discussion of the findings and conclusions reached during the meeting. This portion of the meeting will be closed to the public. *Basis for Closure:* The Executive Session will likely include discussions of sensitive infrastructure information concerning system threats and explicit physical/cyber vulnerabilities related to current emergency communications capabilities and the use of national security and emergency preparedness services over the next generation networks. Public disclosure of such information would heighten awareness of potential vulnerabilities and increase the likelihood of exploitation by terrorists or other motivated adversaries. The Executive Session will occur between 10:30 a.m. and 3:30 p.m. and will involve sensitive information. Pursuant to Section 10(d) of the Federal Advisory Committee Act, Public Law 92-463, as amended (5 U.S.C. App. 1 *et seq.* ), the Department has determined that this discussion will concern matters which, if disclosed, would be likely to frustrate significantly the implementation of a proposed agency action. Accordingly, the relevant portion of this meeting will be closed to the public pursuant to the authority set forth in 5 U.S.C. 552b(c)(9)(B). Dated: April 5, 2006. Peter M. Fonash, Deputy Manager National Communications System. [FR Doc. 06-3994 Filed 4-26-06; 8:45 am]

Connectionstraces to 4

Traces to 4 documents

U.S. Code

CFR

5 references not yet in our index